MAPT and Alzheimer disease: Azelaic acid has also been identified as a potential biomarker in urine for personalized healthcare in AD diagnosis [96] as its level correlates negatively with Aβ42 in cerebrospinal fluid (CSF) and positively with the CSF tau levels.